Our mission is to help people see more clearly and improve their quality of life.

Our technology is clinically proven to improve vision across a variety of vision conditions and is FDA-cleared for amblyopia over age 9. RevitalVision enhances the brain's visual processing, enabling significant vision improvements beyond standard eye care, truly making a difference

Meet the Team

Yair Yahav
Founder & CEO
Yogev Shamay
Co-founder & CTO
Yuval Ron-Ruhama
COO
Charles Morris
General Manager –N. America
Yonina Thee
Clinical Specialist
Inbal Sasson
Clinical Research Manager
Shlomo Abramson
Clinical Service Manager
Rona Erlich
Marketing Director

Board

Yariv Baron
Director
Dr. Shulamit Hadi
Director
Alon Reshef
Director & Shareholder
Simon Kan
Director

Advisory Board

Amir Belson, M.D.
Advisory Board
Prof. Richard W. Hertle (MD)
Scientific & Clinical Advisor
Prof. Ramesh

Kekunnaya (MD)
Scientific & Clinical Advisor
Dr. Sarah Maling (MD)
Advisory Board
Mike Turner
Advisory Board
Prof. Yair Morad (MD)
Scientific & Clinical Advisor

Latest News and Events

News icon

October 2022

Presenting at the ACADEMY 2022 SAN DIEGO

The American Academy of Optometry’s annual meeting
News icon

October 2022

RevitalVision at EPOS 2022 Munich

47th Meeting of European Paediatric Ophthalmological Society
News icon

September 2022

Israel: A beacon of light helping with sight

This special feature article in GeekTime profiles innovative optics treatments and technologies from leading start-ups.

To the full article
News icon

RevitalVision will present at ESCRS2022

We will be presenting at the 40th annual congress of The European Society for Cataract and Refractive Surgery (ESCRS) in Milan, Italy, from 16-19 September 2022.

 

For more information on the ESCRS congress
News icon

May2022

RevitalVision at the AAO 2022 mid year press relase

We are proud to be one of the 10 companies chosen by the AOA committee to be eye care game changers and will impact how optometrists will practice in years to come!!
AAO 2022 mid year press relase
News icon

March 2022

New randomized controlled trial on RevitalVision

Effects of Perceptual Learning on Deprivation Amblyopia in Children with Limbal Dermoid: A Randomized Controlled Trial

The study compared 2 groups of children with amblyopia after corneal transplant : One group received standard patching therapy and the second group received patching + RevitalVision.

The group that underwent RevitalVision therapy experienced statistically significant improvement in vision.

Read the full study
1 2 3 4 5 6